# A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)

> **NCT04956666** · PHASE2 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 75 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Lyophilized S95014

## Key facts

- **NCT ID:** NCT04956666
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-15
- **Primary completion:** 2023-01-23
- **Final completion:** 2023-01-23
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-12-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04956666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04956666, "A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04956666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*